Cara Therapeutics | CARA - PE Price to Earnings


Cara Therapeutics reported 0.49 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
Acadia Pharmaceuticals 11.33 1.25 Jun/2026
Cara Therapeutics 0.49 27.28 Mar/2026
Chugai Pharma 24.32 4.56 Jun/2026
Cipla 35.82 12.26 Jun/2026
Clal Biotechnology 11.67 2.62 Dec/2022
Compugen 5.45 1.39 Mar/2026
CSL 16.16 9.59 Dec/2025
Grifols 11.2 1.08 Dec/2025
Halozyme Therapeutics 11.35 11.8 Mar/2026
J&J 29.43 4.9 Jun/2026
Neurocrine Biosciences 22.1 5.99 Jun/2026
Pacira 35.68 2.9 Jun/2026
Pfizer 11.48 2.16 Jun/2026
RedHill Biopharma 0.04 0.03 Jun/2025
Supernus Pharmaceuticals 65.37 21.16 Jun/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023